Member of the US House of Representatives (Republican - Texas)
Ron Paul, MD, Member of the US House of Representatives (R-TX), wrote the following in an Apr. 27, 2005 letter to the US Food and Drug Administration signed by 23 other members of the US House of Representatives:
"After deferring to the DEA, your release reads that, 'FDA is the sole federal agency that approves drug products as safe and effective for intended indications.' Why then has the FDA failed to respond to the 1999 Institute of Medicine (IOM) report which concluded that marijuana's active components are potentially effective in treating pain, nausea, the anorexia of AIDS wasting, and other symptoms, and should be tested rigorously in clinical trials?
It perplexes us that even though the FDA is responsible for protecting public health, the agency has failed to respond adequately to the IOM's findings seven years after the study's publication date. Additionally, this release failed to make note of the FDA's Investigational New Drug (IND) Compassionate Access Program, which allowed patients with certain medical conditions to apply with the FDA to receive federal marijuana. Currently, seven people still enlisted in this program continue to receive marijuana through the federal government.
The existence of this program is an example of how the FDA could allow for the legal use of a drug, such as medical marijuana, without going through the 'well-controlled' series of steps that other drugs have to go through if there is a compassionate need."